171 related articles for article (PubMed ID: 23651223)
21. Smac mimetics increase cancer cell response to chemotherapeutics in a TNF-α-dependent manner.
Probst BL; Liu L; Ramesh V; Li L; Sun H; Minna JD; Wang L
Cell Death Differ; 2010 Oct; 17(10):1645-54. PubMed ID: 20431601
[TBL] [Abstract][Full Text] [Related]
22. Biomarker profile for prediction of response to SMAC mimetic monotherapy in pediatric precursor B-cell acute lymphoblastic leukemia.
Zinngrebe J; Schlichtig F; Kraus JM; Meyer M; Boldrin E; Kestler HA; Meyer LH; Fischer-Posovszky P; Debatin KM
Int J Cancer; 2020 Jun; 146(11):3219-3231. PubMed ID: 31749151
[TBL] [Abstract][Full Text] [Related]
23. Structural basis for bivalent Smac-mimetics recognition in the IAP protein family.
Cossu F; Milani M; Mastrangelo E; Vachette P; Servida F; Lecis D; Canevari G; Delia D; Drago C; Rizzo V; Manzoni L; Seneci P; Scolastico C; Bolognesi M
J Mol Biol; 2009 Sep; 392(3):630-44. PubMed ID: 19393243
[TBL] [Abstract][Full Text] [Related]
24. Birinapant (TL32711), a bivalent SMAC mimetic, targets TRAF2-associated cIAPs, abrogates TNF-induced NF-κB activation, and is active in patient-derived xenograft models.
Benetatos CA; Mitsuuchi Y; Burns JM; Neiman EM; Condon SM; Yu G; Seipel ME; Kapoor GS; Laporte MG; Rippin SR; Deng Y; Hendi MS; Tirunahari PK; Lee YH; Haimowitz T; Alexander MD; Graham MA; Weng D; Shi Y; McKinlay MA; Chunduru SK
Mol Cancer Ther; 2014 Apr; 13(4):867-79. PubMed ID: 24563541
[TBL] [Abstract][Full Text] [Related]
25. Cyclopeptide Smac mimetics as antagonists of IAP proteins.
Sun H; Liu L; Lu J; Qiu S; Yang CY; Yi H; Wang S
Bioorg Med Chem Lett; 2010 May; 20(10):3043-6. PubMed ID: 20443226
[TBL] [Abstract][Full Text] [Related]
26. Novel second mitochondria-derived activator of caspases (Smac) mimetic compounds sensitize human leukemic cell lines to conventional chemotherapeutic drug-induced and death receptor-mediated apoptosis.
Servida F; Lecis D; Scavullo C; Drago C; Seneci P; Carlo-Stella C; Manzoni L; Polli E; Lambertenghi Deliliers G; Delia D; Onida F
Invest New Drugs; 2011 Dec; 29(6):1264-75. PubMed ID: 20614162
[TBL] [Abstract][Full Text] [Related]
27. SMAC mimetic Debio 1143 synergizes with taxanes, topoisomerase inhibitors and bromodomain inhibitors to impede growth of lung adenocarcinoma cells.
Langdon CG; Wiedemann N; Held MA; Mamillapalli R; Iyidogan P; Theodosakis N; Platt JT; Levy F; Vuagniaux G; Wang S; Bosenberg MW; Stern DF
Oncotarget; 2015 Nov; 6(35):37410-25. PubMed ID: 26485762
[TBL] [Abstract][Full Text] [Related]
28. Antitumor activity of a novel homodimeric SMAC mimetic in ovarian carcinoma.
Gatti L; De Cesare M; Ciusani E; Corna E; Arrighetti N; Cominetti D; Belvisi L; Potenza D; Moroni E; Vasile F; Lecis D; Delia D; Castiglioni V; Scanziani E; Seneci P; Zaffaroni N; Perego P
Mol Pharm; 2014 Jan; 11(1):283-93. PubMed ID: 24256025
[TBL] [Abstract][Full Text] [Related]
29. DEBIO 1143, an IAP inhibitor, reverses carboplatin resistance in ovarian cancer cells and triggers apoptotic or necroptotic cell death.
Thibault B; Genre L; Le Naour A; Broca C; Mery E; Vuagniaux G; Delord JP; Wiedemann N; Couderc B
Sci Rep; 2018 Dec; 8(1):17862. PubMed ID: 30552344
[TBL] [Abstract][Full Text] [Related]
30. Proteasome inhibitors and Smac mimetics cooperate to induce cell death in diffuse large B-cell lymphoma by stabilizing NOXA and triggering mitochondrial apoptosis.
Dietz A; Dalda N; Zielke S; Dittmann J; van Wijk SJL; Vogler M; Fulda S
Int J Cancer; 2020 Sep; 147(5):1485-1498. PubMed ID: 32170726
[TBL] [Abstract][Full Text] [Related]
31. Nonpeptidic and potent small-molecule inhibitors of cIAP-1/2 and XIAP proteins.
Sun H; Lu J; Liu L; Yi H; Qiu S; Yang CY; Deschamps JR; Wang S
J Med Chem; 2010 Sep; 53(17):6361-7. PubMed ID: 20684551
[TBL] [Abstract][Full Text] [Related]
32. Synthetic Smac/DIABLO peptides enhance the effects of chemotherapeutic agents by binding XIAP and cIAP1 in situ.
Arnt CR; Chiorean MV; Heldebrant MP; Gores GJ; Kaufmann SH
J Biol Chem; 2002 Nov; 277(46):44236-43. PubMed ID: 12218061
[TBL] [Abstract][Full Text] [Related]
33. Designing Smac-mimetics as antagonists of XIAP, cIAP1, and cIAP2.
Cossu F; Mastrangelo E; Milani M; Sorrentino G; Lecis D; Delia D; Manzoni L; Seneci P; Scolastico C; Bolognesi M
Biochem Biophys Res Commun; 2009 Jan; 378(2):162-7. PubMed ID: 18992220
[TBL] [Abstract][Full Text] [Related]
34. Smac peptide potentiates TRAIL- or paclitaxel-mediated ovarian cancer cell death in vitro and in vivo.
Mao HL; Pang Y; Zhang X; Yang F; Zheng J; Wang Y; Liu P
Oncol Rep; 2013 Feb; 29(2):515-22. PubMed ID: 23151974
[TBL] [Abstract][Full Text] [Related]
35. Design, synthesis and biological evaluation of new bivalent quinazoline analogues as IAP antagonists.
Bae I; Kim D; Choi J; Kim J; Kim M; Park B; Kim YH; Ahn YG; Hyung Kim H; Kim DK
Bioorg Med Chem Lett; 2021 Feb; 34():127676. PubMed ID: 33166687
[TBL] [Abstract][Full Text] [Related]
36. Design, synthesis, and evaluation of potent, nonpeptidic mimetics of second mitochondria-derived activator of caspases.
Sun W; Nikolovska-Coleska Z; Qin D; Sun H; Yang CY; Bai L; Qiu S; Wang Y; Ma D; Wang S
J Med Chem; 2009 Feb; 52(3):593-6. PubMed ID: 19138149
[TBL] [Abstract][Full Text] [Related]
37. Role of XIAP in inhibiting cisplatin-induced caspase activation in non-small cell lung cancer cells: a small molecule Smac mimic sensitizes for chemotherapy-induced apoptosis by enhancing caspase-3 activation.
Checinska A; Hoogeland BS; Rodriguez JA; Giaccone G; Kruyt FA
Exp Cell Res; 2007 Apr; 313(6):1215-24. PubMed ID: 17291493
[TBL] [Abstract][Full Text] [Related]
38. A novel Smac mimetic APG-1387 demonstrates potent antitumor activity in nasopharyngeal carcinoma cells by inducing apoptosis.
Li N; Feng L; Han HQ; Yuan J; Qi XK; Lian YF; Kuang BH; Zhang YC; Deng CC; Zhang HJ; Yao YY; Xu M; He GP; Zhao BC; Gao L; Feng QS; Chen LZ; Yang L; Yang D; Zeng YX
Cancer Lett; 2016 Oct; 381(1):14-22. PubMed ID: 27424523
[TBL] [Abstract][Full Text] [Related]
39. A Smac-mimetic sensitizes prostate cancer cells to TRAIL-induced apoptosis via modulating both IAPs and NF-kappaB.
Dai Y; Liu M; Tang W; Li Y; Lian J; Lawrence TS; Xu L
BMC Cancer; 2009 Nov; 9():392. PubMed ID: 19895686
[TBL] [Abstract][Full Text] [Related]
40. LCL161, a SMAC-mimetic, Preferentially Radiosensitizes Human Papillomavirus-negative Head and Neck Squamous Cell Carcinoma.
Yang L; Kumar B; Shen C; Zhao S; Blakaj D; Li T; Romito M; Teknos TN; Williams TM
Mol Cancer Ther; 2019 Jun; 18(6):1025-1035. PubMed ID: 31015310
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
